Preparation and Evaluation of the Cytoprotective Activity of Micelles with DSPE-PEG-C60 as a Carrier Against Doxorubicin-Induced Cytotoxicity

Xu, Bo; Ding, Zhongpeng; Hu, Ying; Zhang, Ting; Shi, Senlin; Yu, Guangmao; Qi, Xuchen

doi:10.3389/fphar.2022.952800

Cited by 7 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies have reported that fullerenols exhibit protective effects against doxorubicin (DOX)-induced cardiotoxicity, hepatotoxicity and nephrotoxicity in rats subjected to high doses of DOX in vivo. The cytoprotective effects of fullerenols against doxorubicin (DOX)-induced damage in normal cells in vitro were also observed in our previous studies [17]. In the present study, an investigation was conducted to examine the antioxidant properties of C60(OH) 22 and its amphiphilic derivative DSPE-PEG-C60 in protecting normal HK-2 and L02 cells against cytotoxicity induced by NCTD.…”

Section: Discussionsupporting

confidence: 65%

“…The findings indicated that the fullerenol (C60)-modified micelles demonstrated reduced cytotoxicity in normal cell lines (L02, H9c2, GES-1) in comparison to free DOX in vitro. The results also showed that micelles modified with C60 exhibited a reduction in intracellular ROS in the H9c2 cells in comparison to free DOX [17]. However, it is still uncertain whether fullerenol has the potential to play a role against the oxidative stress induced by other anticancer drugs in normal tissues.…”

Section: Introductionmentioning

confidence: 93%

See 1 more Smart Citation

Norcantharidin-Encapsulated C60-Modified Nanomicelles: A Potential Approach to Mitigate Cytotoxicity in Renal Cells and Simultaneously Enhance Anti-Tumor Activity in Hepatocellular Carcinoma Cells

Ding,

Xu,

Zhang

et al. 2023

Molecules

Self Cite

View full text Add to dashboard Cite

Objective: The objective of this study was to examine the preparation process of DSPE-PEG-C60/NCTD micelles and assess the impact of fullerenol (C60)-modified micelles on the nephrotoxicity and antitumor activity of NCTD. Method: The micelles containing NCTD were prepared using the ultrasonic method and subsequently optimized and characterized. The cytotoxicity of micelles loaded with NCTD was assessed using the CCK-8 method on human hepatoma cell lines HepG2 and BEL-7402, as well as normal cell lines HK-2 and L02. Acridine orange/ethidium bromide (AO/EB) double staining and flow cytometry were employed to assess the impact of NCTD-loaded micelles on the apoptosis of the HK-2 cells and the HepG2 cells. Additionally, JC-1 fluorescence was utilized to quantify the alterations in mitochondrial membrane potential. The generation of reactive oxygen species (ROS) following micelle treatment was determined through 2′,7′-dichlorofluorescein diacetate (DCFDA) staining. Results: The particle size distribution of the DSPE-PEG-C60/NCTD micelles was determined to be 91.57 nm (PDI = 0.231). The zeta potential of the micelles was found to be −13.8 mV. The encapsulation efficiency was measured to be 91.9%. The in vitro release behavior of the micelles followed the Higuchi equation. Cellular experiments demonstrated a notable decrease in the toxicity of the C60-modified micelles against the HK-2 cells, accompanied by an augmented inhibitory effect on cancer cells. Compared to the free NCTD group, the DSPE-PEG-C60 micelles exhibited a decreased apoptosis rate (12%) for the HK-2 cell line, lower than the apoptosis rate observed in the NCTD group (36%) at an NCTD concentration of 75 μM. The rate of apoptosis in the HepG2 cells exhibited a significant increase (49%), surpassing the apoptosis rate observed in the NCTD group (24%) at a concentration of 150 μM NCTD. The HK-2 cells exhibited a reduction in intracellular ROS and an increase in mitochondrial membrane potential (ΔψM) upon exposure to C60-modified micelles compared to the NCTD group. Conclusions: The DSPE-PEG-C60/NCTD micelles, as prepared in this study, demonstrated the ability to decrease cytotoxicity and ROS levels in normal renal cells (HK-2) in vitro. Additionally, these micelles showed an enhanced antitumor activity against human hepatocellular carcinoma cells (HepG2, BEL-7402).

show abstract

Section: Discussionsupporting

confidence: 65%

Section: Introductionmentioning

confidence: 93%

Norcantharidin-Encapsulated C60-Modified Nanomicelles: A Potential Approach to Mitigate Cytotoxicity in Renal Cells and Simultaneously Enhance Anti-Tumor Activity in Hepatocellular Carcinoma Cells

Ding,

Xu,

Zhang

et al. 2023

Molecules

Self Cite

View full text Add to dashboard Cite

show abstract

“…Beihua et al 85 we could not consider the report as complete since the authors did not complete the investigation after sacrificing the animals.…”

Section: Frl As Potential Organ Protector In Oncology Treatmentsmentioning

confidence: 98%

“…The most significant research investigations related to the potential applicability of FRL as organ-protectors in oncology treatments are listed in Table 2. [11][12][13][14][15]19,20,22,24,[75][76][77][78][79][80][81][82][83][84][85] Our extended research team has been publishing several papers focusing on the applicability of FRLs as antioxidants to protect organs from the side effects of chemotherapy [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] and radiotherapy. 11,77,82 Most of the tests were performed with intraperitoneal injection of FRL, [11][12][13][14][15][16][18][19]…”

Section: Frl As Potential Organ Protector In Oncology Treatmentsmentioning

confidence: 99%

Potential Medical Use of Fullerenols After Two Decades of Oncology Research

Injac

2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Fullerenes are carbon molecules that are found in nature in various forms. They are composed of hexagonal and pentagonal rings that create closed structures. Almost 4 decades ago, fullerenes were identified in the form of C60 and C70, and following the award of the Nobel Prize in Chemistry for this discovery in 1996, many laboratories started working on their water-soluble derivatives that could be used in different industries, including pharmaceutical industries. One of the first fullerene forms that was the focus of different research groups was fullerenol, C60(OH) n ( n = 2-44). Both in-vitro and in-vivo studies have shown that polyhydroxylate fullerene derivatives can potentially be used as either antioxidative agents or cytostatics (depending on their co-administration, forms, and concentration/dose) in biological systems. The current review aimed to present a critical view of the potential applications and limitations of fullerenols in oncology, as understood from the past 2 decades of research.

show abstract

“…MaterialType Refs PEG-DSPE PEG-lipid conjugate[61,62] PEG-DSPC PEG-lipid conjugate[61] PEG-PCL PEG-lipid conjugate[63,64] PEG-PE/PG/PS PEG-phospholipid conjugate[65,66] PEG-PLGA/PEG PEG-polymer conjugate[67] …”

mentioning

confidence: 99%

Smart Lipid‐Based Nanoparticles in Lung Cancer Treatment: Current Status and Future Directions

Shahrivar,

Fakhr,

Abbasgholinejad

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer‐related deaths worldwide, and conventional treatments for the disease often fall short. Smart nanoparticles (NPs) are emerging as a promising strategy for the treatment of lung cancer, owing to their ability to selectively deliver therapeutic agents to cancer cells while minimizing off‐target effects. Smart NPs can respond to specific stimuli such as changes in pH, temperature, or enzymes, allowing them to release their cargo only when triggered. Among the various types of smart NPs, lipid‐based NPs, including liposomes, solid lipid nanoparticles, cubosomes, and extracellular vesicles, have garnered the highest interest due to their biocompatibility, low toxicity, and versatility in encapsulating a wide variety of drugs and genetic material. This review discusses the current status of smart lipid‐based NPs in lung cancer treatment, including recent advances in targeting strategies, stimuli‐responsive NPs, and combination therapies. The challenges and opportunities associated with translating smart lipid‐based NPs for lung cancer treatment into clinical applications are also discussed. This review highlights the potential of smart lipid‐based NPs to revolutionize lung cancer treatment and improve patient outcomes.

show abstract

Preparation and Evaluation of the Cytoprotective Activity of Micelles with DSPE-PEG-C60 as a Carrier Against Doxorubicin-Induced Cytotoxicity

Cited by 7 publications

References 35 publications

Norcantharidin-Encapsulated C60-Modified Nanomicelles: A Potential Approach to Mitigate Cytotoxicity in Renal Cells and Simultaneously Enhance Anti-Tumor Activity in Hepatocellular Carcinoma Cells

Norcantharidin-Encapsulated C60-Modified Nanomicelles: A Potential Approach to Mitigate Cytotoxicity in Renal Cells and Simultaneously Enhance Anti-Tumor Activity in Hepatocellular Carcinoma Cells

Potential Medical Use of Fullerenols After Two Decades of Oncology Research

Smart Lipid‐Based Nanoparticles in Lung Cancer Treatment: Current Status and Future Directions

Contact Info

Product

Resources

About